Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series
Year: 2025
Type: article
Study design: Case Report
Abstract: BACKGROUND: Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) is a novel non-surgical alternative to levodopa/carbidopa intestinal gel (LCIG) for advanced Parkinson's disease (aPD), but real-world switch data remain limited. OBJECTIVES: To describe the feasibility, safety, and clinical effects of switching from LCIG to CSFLI. METHODS: We retrospectively reviewed eight aPD patients switched from LCIG to CSFLI at a single center between November 2024 and May 2025. Motor and non-motor symptoms, quality of life, and levodopa equivalent daily doses were assessed at baseline (M0) and six months (M6). RESULTS: Small but significant improvements occurred in UPDRS part I, III, and IV and PDQ-8 scores at M6. Total LEDD remained stable. CSFLI was well tolerated with mild local skin reactions. CONCLUSION: Switching from LCIG to CSFLI is feasible and safe, providing stable dopaminergic delivery with modest symptomatic benefits in selected aPD patients.
DOI: 10.1002/mdc3.70317
Institutions: Université Paris Cité, Hôpital Rothschild, Fondation de Rothschild
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4413604834